Nieuwkoop Jeroen 4
4 · Hyperliquid Strategies Inc · Filed Jan 7, 2026
Insider Transaction Report
Form 4
Nieuwkoop Jeroen
Chief Operating Officer
Transactions
- Other
Common Stock
2025-12-04+31,840→ 31,840 total
Footnotes (1)
- [F1]On December 2, 2025, Hyperliquid Strategies Inc (the "Company") completed its previously announced business combination (the "Closing"), pursuant to the Business Combination Agreement, dated as of July 11, 2025 (as amended on September 22, 2025, the "BCA"), by and among the Company, Sonnet BioTherapeutics Holdings, Inc. ("Sonnet"), Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC . In connection with the Closing, Rorschach Capital LLC received an aggregate of 6,580,800 shares of common stock, par value $0.01 per share, of the Company (the "Common Stock"). On December 4, 2025, Rorschach Capital LLC distributed 31,840 shares of Common Stock to Mr. Nieuwkoop, a member of Rorschach Capital LLC.